Shares of biotechnology company Ocugen, Inc. (OCGN) shares are down 11 percent on Wednesday's trading thus breaking the stock's upward trend since the past few days. The stock has been on an upward trajectory since submitting NDA for Phase 3 clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26.
Currently at $13.92, the stock has traded between $0.27 and $18.77 during the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News